Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 2 Gastro-enteropancreatic neuroendocrine tumor 2 Stomach Neoplasms 1 Solid Tumors 1 Prostatic Neoplasms 1 Prostate Cancer Metastatic 1 Pancreatic Neoplasms 1 Pancreatic Diseases 1 Neuroectodermal Tumors 1 Neoplasms, Nerve Tissue 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasms 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Endocrine System Diseases 1 Endocrine Gland Neoplasms 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 3 lenvatinib 3 gallium 68 PSMA-11 2 apatinib 2 Protons 2 Magnetic Resonance Spectroscopy 2 Imatinib Mesylate 2 Epirubicin 2 Cisplatin 2 Carboplatin 2 Axitinib 2 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2 tislelizumab 1 regorafenib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 anlotinib 1 amivantamab 1 abemaciclib 1 Tretinoin 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Sunitinib 1 Standard of Care 1 Specimen Handling 1 Radiotherapy, Intensity-Modulated 1 Radiosurgery 1 Radiation 1 Pemetrexed 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Adenoid Cystic × Lutetium × Clear all

NCT06199453 2025-02-10

LuRM_ACC/2023

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 2 Withdrawn

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡